Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Analgesics

Limited evidence for use of gabapentinoids to treat chronic low back pain

Analysis of randomised controlled trials assessing the use of gabapentinoids for chronic low back pain confirms that evidence on their use is limited and the drug should be used with caution. 

Pregabalin and gabapentin are increasingly used for nonspecific chronic low back pain (CLBP), despite a lack of evidence. NHS guidelines have highlighted concerns about their off-label use and the potential for misuse. There have also been concerns about their increased prescribing for various non-cancer pain indications.

Researchers searched MEDLINE, EMBASE and Cochrane databases for randomised controlled trials reporting the use of gabapentinoids for CLBP of >3 months’ duration in adult patients.

From the eight studies included, it was found that those comparing gabapentin with placebo showed minimal improvement of pain, and in those comparing pregabalin with other analgesic medications, greater improvements were seen in the ‘other analgesic’ group. Furthermore, compared with placebo, adverse events such as dizziness, fatigue and visual disturbances were more commonly reported by patients taking gabapentin.

Reporting in PLoS Medicine (online, 15 August 2017), the researchers conclude that existing evidence on the use of gabapentinoids in CLBP is limited, and that gabapentinoids should be used with caution[1].

Citation: Clinical Pharmacist DOI: 10.1211/CP.2017.20203489

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Introduction to Renal Therapeutics

    Introduction to Renal Therapeutics

    Introduction to Renal Therapeutics covers all aspects of drug use in renal failure. Shows the role of the pharmacist in patient care for chronic kidney disease.

    £37.00Buy now
  • Introduction to Statistics in Pharmaceutical Clinical Trials

    Introduction to Statistics in Pharmaceutical Clinical Trials

    An innovative book which presents statistics in the context of clinical trials conducted during pharmaceutical drug development.

    £37.00Buy now
  • Clarke's Analysis of Drugs and Poisons

    Clarke's Analysis of Drugs and Poisons

    Clarke's Analysis of Drugs and Poisons is the definitive reference source of analytical data for drugs and poisons.

    £520.00Buy now
  • Nutraceuticals

    Nutraceuticals

    This authoritative text assesses the medical and scientific evidence for the use of nutraceuticals. Includes monographs on 25 nutraceuticals such as soy and tea.

    £37.00Buy now
  • Drugs and the Liver

    Drugs and the Liver

    Drugs and the Liver assists practitioners in making pragmatic choices for their patients. It enables you to assess liver function and covers the principles of drug use in liver disease.

    £37.00Buy now
  • Workplace Drug Testing

    Workplace Drug Testing

    Explains drug testing regulatory frameworks and all aspects of drug analysis. Case studies of successful programmes are included.

    £79.00Buy now

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Supplementary images

  • lower back pain xray of spine

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.